[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shen Chun-Hong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100545917","neural-autoantibody-prevalence-in-new-onset-focal-seizures-of-unknown-etiology-100545917",false,"NCT06388161","Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology","Neural Autoantibody Prevalence in Patients With New-onset Focal Seizures of Unknown Etiology and a Predictive Scoring Scale","Inclusion Criteria:\n\n* Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months\n* Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics\n* There is no obvious suspicion of autoimmune encephalitis\n* Written informed consent and sera are obtained\n* Cerebrospinal fluid test must be conducted, when patients have detectable serum autoantibodies\n\nExclusion Criteria:\n\n* Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.\n* Written informed consent are not obtained\n* Loss of follow-up","ALL","14 Years","100 Years",{"count":20,"type":21},300,"ESTIMATED","1 Year","OBSERVATIONAL","Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.\n\nIt is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.",[26,27],"Epilepsy","Encephalitis Autoimmune","RECRUITING","2025-08-20",{"date":31,"type":32},"2025-08-27","ACTUAL",{"date":34,"type":32},"2023-08-01",{"date":36,"type":21},"2030-12-31",{"name":38,"class":39},"Shen Chun-Hong","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100545918","idiopathic-generalized-epilepsy-syndromes-100545918","NCT06388174","Idiopathic Generalized Epilepsy Syndromes","Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes","Inclusion Criteria:\n\n* Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.\n* Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.\n* Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.\n* Sign the informed consent forms.\n\nExclusion Criteria:\n\n* Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.\n* Lost to follow-up","4 Years","40 Years",{"count":51,"type":21},200,"The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.\n\nAccording to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.",[26,54],"Epilepsy, Idiopathic Generalized",{"date":31,"type":32},{"date":57,"type":32},"2023-01-01",{"date":59,"type":21},"2033-12-31",{"name":38,"class":39},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":18,"enrollmentInfo":69,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":40},"100529384","a-prospective-study-to-evaluate-clinical-outcomes-in-anti-lgi1-encephalitis-100529384","NCT06173076","A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis","A Prospective Study to Evaluate Clinical Outcomes in Patients With Anti-leucine-rich Glioma-inactivated 1 Encephalitis","Inclusion Criteria:\n\n1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.\n2. Newly diagnosed, and during the acute stage before study enrollment.\n3. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. with the diagnosis of epilepsy, stroke, cerebral trauma, and\u002For other nervous system disease prior to the onset of encephalitis.\n2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.\n3. Lost to follow-up.","18 Years",{"count":70,"type":21},60,"Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.\n\nSo far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.",[73,74],"Autoimmune Encephalitis","Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis",{"date":31,"type":32},{"date":77,"type":32},"2022-05-18",{"date":79,"type":21},"2032-12-31",{"name":38,"class":39},""]